Topical oropharyngeal vancomycin to control methicillin resistant
1 / 9

- PowerPoint PPT Presentation

  • Uploaded on

Topical oropharyngeal vancomycin to control methicillin resistant Staphylococcus aureus lower airway infection in ventilated patients. L. Silvestry et al . 2010. Minerva Anestesiol 76:193–202. Mark Lopez Yessenia Velazco Micr 454L 04/07/10. Objectives.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about '' - shelagh-kennefick

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
L silvestry et al 2010 minerva anestesiol 76 193 202

Topical oropharyngeal vancomycin to control methicillin resistant Staphylococcus aureus lower airway infection in ventilated patients

L. Silvestry et al. 2010. Minerva Anestesiol 76:193–202

Mark Lopez

Yessenia Velazco

Micr 454L


Objectives resistant

  • To evaluate the effectiveness of two different policies for topical vancomycin administration on oropharyngeal carriage and lower airway infection due to MRSA.

  • To monitor the emergence of vancomycin-resistant enterococci (VRE) and vancomycin-intermediate Staphylococcus aureus (VISA).

Experimental approach
Experimental Approach resistant

  • Subject population: July 2002 – June 2005

    Patients over 18 years old

    Required mechanical ventilation for >72 hours.

  • Study intervention: Period one (07/2002 – 12/2003)Vancomycin to all

    MRSA carriers

    Period two (01/2004 – 06/2005) Vancomycin to all


  • Antibiotic and non antibiotic policies of the unit:

    SDD (enteral and parental antimicrobials, hygiene, and

    surveillance culture of throat and rectum)

  • Microbiology: Columbia plus 5% sheep blood, mannitol salt agar, McConkey,

    Chocolate Haemophilus, Columbia colistin-nalidixic acid plus 5% sheep

    blood, and yeast agar

  • Statistical analysis: Fisher’s exact test, Chi-square (X2), Student’s t-test

    Significance was set at 0.05

Results resistant

Figure 1. Oropharyngeal carriage indices of MRSA. CI: carriage index

Main findings
Main Findings resistant

  • The immediate administration of topical oropharyngeal vancomycin on ICU admission significantly reduced the levels of MRSA carriage and lower airway infection compared with patients whom topical oropharyngeal vancomycin was only given after MRSA carriage was detected.

  • Neither VRE nor VISA were isolated from surveillance and diagnostic samples during the study period.

Discussion resistant

  • The effectiveness of MRSA carriage prophylaxis over MRSA carriage treatment may be explained by:

    1. MRSA carriage treatment caused delay and promoted

    overgrowth, colonization, and subsequent infection of

    the lower airways

    2. MRSA carriage prophylaxis protected patients against

    MRSA acquisition, and MRSA found during admission

    was cleared promptly by vancomycin administration.

  • Treatment of populations without MRSA may lead to the development of more resistant strains of MRSA

    • No evidence of vancomycin-resistant strains found in test subjects.

Critiques resistant

  • Two different consecutive time periods of data acquisition

    -Epidemiological changes in frequency of MRSA in general population


  • No control group given placebo

    -Cannot say with certainty that changes in MRSA frequency are due to vancomycin treatment

  • Variations in sample populations

    -Differing underlying medical issues may increase or decrease vulnerability to MRSA

Take home message
Take Home Message resistant

1. Prophylactic treatment of populations with vancomycin is more effective at controlling MRSA outbreaks than treatment of individual MRSA infections.

2. Treatment with vancomycin may reduce or eliminate MRSA infections in the short term, but may cause problems in the future by encouraging more resistant forms of MRSA to develop.

Questions? resistant